PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1100117
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1100117
The North America pterygium drug market is projected to register a substantial CAGR of 5.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
North America Pterygium Drug Market, By Type (Progressive Pterygium and Atrophic Pterygium), Stages (Stage 2, Stage 3, Stage 1, Stage 4), Treatment (Artificial Tears/Topical Lubricants and Steroid Eye Drops.), Formulation (Eye Drops, Eye Ointments, Others), Mode of Purchase (Prescription and Over the Counter (OTC)), Population Type (Geriatric and Adults), End-User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Increase in healthcare awareness to reduce the risk of eye illnesses
Rising geriatric population
Johnson & Johnson Services, Inc.
Novartis AG
Akorn Operating Company LLC
Bausch & Lomb Incorporated
AbbVie Inc.
Prestige Consumer Healthcare Inc.
Sylentis
Bayer AG
Zydus Group
Amneal Pharmaceuticals LLC
OASIS Medical
Alcon
Santen Pharmaceutical Co.